Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy
Excerpt from the Press Release:
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the completion of enrollment in its Phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD and requiring continued anti-vascular endothelial growth factor (anti-VEGF) treatment who have, or may be at risk for, macular atrophy (MA). Topline data related to safety, tolerability, effect on intraocular complement factor H (CFH) levels and disease-relevant biomarkers of complement regulation is expected in late 2021.
“Both physicians and patients recognize the limitations of anti-VEGF treatment, with approximately a third of patients developing reduced visual acuity and MA over time,” said Samuel Barone, M.D., Chief Medical Officer of Gemini Therapeutics. “The team’s ability to overenroll the study highlights the unmet need and the potential for GEM103 to address these suboptimal outcomes in the setting of regular anti-VEGF therapy and its subsequent depletion in CFH levels causing complement dysfunction.”
“Achieving our enrollment completion target for this trial is another milestone in our GEM103 program’s progress, and we anticipate additional data in 2021 to provide critical information on GEM103’s safety, pharmacokinietcs and biological activity in patients with either dry AMD or those receiving anti-VEGF treatment for wet AMD,” said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. “We look forward to releasing data from this study in patients with wet AMD before year end as we continue to evaluate CFH’s role as the primary endogenous complement regulator and it’s ability to restore retinal homeostasis in AMD.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?